You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
澳洲取消CSL与昆士兰大学新型肺炎疫苗订单 将增购其他药厂疫苗
阿思达克 12-11 14:29
《彭博》报道,澳洲取消由当地生物科技公司CSL与昆士兰大学研发的新型肺炎疫苗订单,涉及5,100万剂。澳洲政府表示,将透过增加购买其他药厂的疫苗来取代大部分CSL的剂量,包括额外订购2,000万剂牛津大学和阿斯利康研发的疫苗,及1,100万剂Novavax(NVAX.US)的疫苗。

澳洲卫生部长格Greg Hunt指,即使取消CSL的疫苗订单,澳洲亦将有超过1.4亿剂疫苗可用,而该国约有2,600万人口,仍是全球疫苗购买和可获得人口比例最高的国家之一。

CSL宣布终止新型肺炎疫苗的第二及三期临床试验,因疫苗有小部分来自人类免疫缺乏病毒HIV,早前试验显示疫苗或导致参与临床人士对爱滋病测试呈假阳性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account